ApoB Polypeptide Mediators for CNS Protein Aggregate Clearance
Find Innovative SolutionsGenerate Solutions
Solution Overview
Problem
Current therapies for neurodegenerative diseases like Alzheimer's and Parkinson's focus on blocking protein synthesis or aggregation, but fail to effectively promote the clearance of toxic protein aggregates such as amyloid beta and tau, which accumulate in the central nervous system, leading to neuronal damage.
Innovation Solution
Development of hybrid or chimeric polypeptides that selectively traffic into the CNS, utilizing a fragment of the apoB protein to target and degrade protein aggregates, such as apoB-secNEP, apoB-Beclin, and apoB-apoE, to enhance clearance via recombinant technologies or gene therapy, allowing for the crossing of the blood-brain barrier.
Engineering Contradictions & Design Principles
Engineering Contradiction Analysis
1Productivity
If polypeptides are used to increase clearance of Aβ aggregates, then clearance efficiency is improved, but the polypeptides cannot enter the CNS or enter at very low levels
Solution Approach 1:
The patent uses apoB as an intermediary protein that serves as a carrier to deliver Aβ-degrading enzymes (such as neprilysin, Beclin, or apoE) into the CNS. The apoB fragment acts as a mediator that crosses the blood-brain barrier and facilitates the entry of therapeutic polypeptides into the central nervous system, resolving the contradiction between improving clearance efficiency and achieving reliable CNS penetration.
2Object-generated harmful factors
If therapies focus on blocking protein synthesis or aggregation, then aggregation is reduced, but clearance of toxic aggregates is not effectively promoted
Solution Approach 1:
Instead of focusing solely on blocking protein synthesis or aggregation (preventive approach), the patent inverts the strategy by directly promoting the clearance and degradation of existing toxic aggregates (curative approach). The therapeutic polypeptides target and degrade accumulated Aβ aggregates, shifting the therapeutic focus from prevention to active removal of harmful substances.
Solution Approach 2:
The patent extracts and delivers specific Aβ-degrading enzymes (such as neprilysin, Beclin, or apoE) into the CNS using apoB as a carrier. This extraction of therapeutic enzymes from peripheral circulation and their targeted delivery into the CNS enables effective clearance of toxic aggregates, addressing the limitation of conventional therapies that do not promote aggregate removal.
Applied Scientific Principles
This section explains which scientific principles are used to turn an abstract innovation direction into a practical engineering solution.
Function Achieved in This Case
The polypeptides effectively increase the clearance of toxic protein aggregates, reducing neuronal damage and providing a novel therapeutic approach for neurodegenerative disorders by facilitating the entry of Aβ-degrading enzymes into the CNS, thereby slowing or reversing disease progression.
Implementation Method 1
utilizing a fragment of the apoB protein to target and degrade protein aggregates, such as apoB-secNEP, apoB-Beclin, and apoB-apoE, to enhance clearance via recombinant technologies or gene therapy, allowing for the crossing of the blood-brain barrier
Implementation Method 2
target protein aggregations, e.g., tau and/or Aβ, for degradation
Data Source
AI summary
The invention provides compositions for increasing the clearance of protein aggregates, and pharmaceutical compositions comprising them, and methods for making and using them, including methods for accelerating protein aggregate clearance in the CNS, e.g., for treating diseases that are characterized by protein aggregation—including some degenerative neurological diseases such as Parkinson's disease. In one aspect, the compositions of the invention specifically target synuclein, beta-amyloid and/or tau protein aggregates, and the methods of the invention can be used to specifically prevent, reverse, slow or inhibit synuclein, beta-amyloid and/or tau protein aggregation. In alternative embodiments, the compositions and methods of the invention, are used to treat, prevent, reverse (partially or completely) or ameliorate (including slowing the progression of) degenerative neurological diseases related to or caused by protein aggregation, e.g., synuclein, beta-amyloid and/or tau protein aggregation. In one aspect, compositions and methods of this invention are used to treat, prevent or ameliorate (including slowing the progression of) Parkinson's disease, fronto-temporal dementia (FTD), Alzheimer's Disease (AD), Lewy body disease (LBD) and Multiple system atrophy (MSA).